VX-765 is a reversible caspase-1 inhibitor that blocks IL-1β maturation and suppresses IL-1β/IL-1R1 signaling, a pathway critically involved in drug-resistant epilepsy via neuroinflammation and blood–brain barrier disruption. This evidence concerns the gene IL1B and epilepsy.